Therapeutic areas for approved biopharmaceutical IND applications in China 2021
In 2021, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved 764 Investigational New Drug (IND) applications of biopharmaceuticals. Almost 60 percent of all approved IND applications were ones concerning antineoplastic drugs.